Qi Sun1, Nicole M Wedick2, Shelley S Tworoger3, An Pan4, Mary K Townsend5, Aedin Cassidy6, Adrian A Franke7, Eric B Rimm8, Frank B Hu8, Rob M van Dam9. 1. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Departments of Nutrition and qisun@hsph.harvard.edu. 2. Division of Preventive and Behavioral Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA; 3. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Departments of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; 4. Department of Epidemiology and Biostatistics, Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China; 5. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Departments of. 6. Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich, Norfolk, United Kingdom; and. 7. University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI. 8. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Departments of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; 9. Nutrition and Saw Swee Hock School of Public Health and Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore;
Abstract
BACKGROUND: Polyphenols are phytochemicals that possess antioxidant and anti-inflammatory properties and improve glucose metabolism in animal experiments, although data from prospective epidemiologic studies examining polyphenol intakes in relation to type 2 diabetes (T2D) risk are inconsistent. OBJECTIVES: We examined urinary excretion of select flavonoid and phenolic acid metabolites, as biomarkers of intake, in relation to T2D risk. METHODS: Eight polyphenol metabolites (naringenin, hesperetin, quercetin, isorhamnetin, catechin, epicatechin, caffeic acid, and ferulic acid) were quantified in spot urine samples by liquid chromatography/mass spectrometry among 1111 T2D case-control pairs selected from the Nurses' Health Study (NHS) and NHSII. RESULTS: Higher urinary excretion of hesperetin was associated with a lower T2D risk after multivariate adjustment: the OR comparing top vs. bottom quartiles was 0.68 (95% CI: 0.49, 0.96), although a linear trend was lacking (P = 0.30). The other measured polyphenols were not significantly associated with T2D risk after multivariate adjustment. However, during the early follow-up period [≤ 4.6 y (median) since urine sample collection], markers of flavanone intakes (naringenin and hesperetin) and flavonol intakes (quercetin and isorhamnetin) were significantly associated with a lower T2D risk. The ORs (95% CIs) comparing extreme quartiles were 0.61 (0.39, 0.98; P-trend: 0.03) for total flavanones and 0.55 (0.33, 0.92; P-trend: 0.04) for total flavonols (P-interaction with follow-up length: ≤ 0.04). An inverse association was also observed for caffeic acid during early follow-up only: the OR was 0.52 (95% CI: 0.32, 0.84; P-trend: 0.03). None of these markers was associated with T2D risk during later follow-up. Metabolites of flavan-3-ols and ferulic acid were not associated with T2D risk in either period. CONCLUSIONS: These results suggest that specific flavonoid subclasses, including flavanones and flavonols, as well as caffeic acid, are associated with a lower T2D risk in relatively short-term follow-up but not during longer follow-up. Substantial within-person variability of the metabolites in single spot urine samples may limit the ability to capture associations with long-term disease risk.
BACKGROUND: Polyphenols are phytochemicals that possess antioxidant and anti-inflammatory properties and improve glucose metabolism in animal experiments, although data from prospective epidemiologic studies examining polyphenol intakes in relation to type 2 diabetes (T2D) risk are inconsistent. OBJECTIVES: We examined urinary excretion of select flavonoid and phenolic acid metabolites, as biomarkers of intake, in relation to T2D risk. METHODS: Eight polyphenol metabolites (naringenin, hesperetin, quercetin, isorhamnetin, catechin, epicatechin, caffeic acid, and ferulic acid) were quantified in spot urine samples by liquid chromatography/mass spectrometry among 1111 T2D case-control pairs selected from the Nurses' Health Study (NHS) and NHSII. RESULTS: Higher urinary excretion of hesperetin was associated with a lower T2D risk after multivariate adjustment: the OR comparing top vs. bottom quartiles was 0.68 (95% CI: 0.49, 0.96), although a linear trend was lacking (P = 0.30). The other measured polyphenols were not significantly associated with T2D risk after multivariate adjustment. However, during the early follow-up period [≤ 4.6 y (median) since urine sample collection], markers of flavanone intakes (naringenin and hesperetin) and flavonol intakes (quercetin and isorhamnetin) were significantly associated with a lower T2D risk. The ORs (95% CIs) comparing extreme quartiles were 0.61 (0.39, 0.98; P-trend: 0.03) for total flavanones and 0.55 (0.33, 0.92; P-trend: 0.04) for total flavonols (P-interaction with follow-up length: ≤ 0.04). An inverse association was also observed for caffeic acid during early follow-up only: the OR was 0.52 (95% CI: 0.32, 0.84; P-trend: 0.03). None of these markers was associated with T2D risk during later follow-up. Metabolites of flavan-3-ols and ferulic acid were not associated with T2D risk in either period. CONCLUSIONS: These results suggest that specific flavonoid subclasses, including flavanones and flavonols, as well as caffeic acid, are associated with a lower T2D risk in relatively short-term follow-up but not during longer follow-up. Substantial within-person variability of the metabolites in single spot urine samples may limit the ability to capture associations with long-term disease risk.
Authors: Lee Hooper; Colin Kay; Asmaa Abdelhamid; Paul A Kroon; Jeffrey S Cohn; Eric B Rimm; Aedín Cassidy Journal: Am J Clin Nutr Date: 2012-02-01 Impact factor: 7.045
Authors: Jennifer A Nettleton; Lisa J Harnack; Carolyn G Scrafford; Pamela J Mink; Leila M Barraj; David R Jacobs Journal: J Nutr Date: 2006-12 Impact factor: 4.798
Authors: Nicole M Wedick; Aoife M Brennan; Qi Sun; Frank B Hu; Christos S Mantzoros; Rob M van Dam Journal: Nutr J Date: 2011-09-13 Impact factor: 3.271
Authors: Paul F Jacques; Aedin Cassidy; Gail Rogers; Julia J Peterson; James B Meigs; Johanna T Dwyer Journal: J Nutr Date: 2013-07-31 Impact factor: 4.798
Authors: Qi Sun; Kimberly A Bertrand; Adrian A Franke; Bernard Rosner; Gary C Curhan; Walter C Willett Journal: Am J Clin Nutr Date: 2016-11-09 Impact factor: 7.045
Authors: Sylvia H Ley; Andres V Ardisson Korat; Qi Sun; Deirdre K Tobias; Cuilin Zhang; Lu Qi; Walter C Willett; JoAnn E Manson; Frank B Hu Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308
Authors: Emily P Laveriano-Santos; María Marhuenda-Muñoz; Anna Vallverdú-Queralt; Miriam Martínez-Huélamo; Anna Tresserra-Rimbau; Elefterios Miliarakis; Camila Arancibia-Riveros; Olga Jáuregui; Ana María Ruiz-León; Sara Castro-Baquero; Ramón Estruch; Patricia Bodega; Mercedes de Miguel; Amaya de Cos-Gandoy; Jesús Martínez-Gómez; Gloria Santos-Beneit; Juan M Fernández-Alvira; Rodrigo Fernández-Jiménez; Rosa M Lamuela-Raventós Journal: Antioxidants (Basel) Date: 2022-06-14
Authors: Xiaohui Guo; Anna Tresserra-Rimbau; Ramón Estruch; Miguel A Martínez-González; Alexander Medina-Remón; Olga Castañer; Dolores Corella; Jordi Salas-Salvadó; Rosa M Lamuela-Raventós Journal: Oxid Med Cell Longev Date: 2016-01-04 Impact factor: 6.543